| Use of Pfizer-BioNTech COVID-19 vaccine: Clinical considerations | Centers for Disease Control and Prevention | 
|---|---|
| Centers for Disease Control and Prevention | Centers for Disease Control and Prevention | 
| Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera | Information about COVID-19 vaccines for people with allergies | 
|---|---|
| Interim considerations for COVID-19 vaccination of healthcare personnel and long-term care facility residents | Pfizer-BioNTech vaccine: Fact sheet for recipients and caregivers | 
| Officials discuss COVID-19 vaccine deliveries prioritization criteria | Vaccine Adverse Event Reporting System | 
|---|---|
| FDA takes additional action in fight against COVID-19 by issuing emergency use authorization for second COVID-19 vaccine | COVID-19 vaccines and allergic reactions |